Predictors of pulmonary tuberculosis treatment outcomes in South Korea: a prospective cohort study, 2005-2012

Hongjo Choi, Myungsun Lee, Ray Y Chen, Youngran Kim, Soyoung Yoon, Joon Sung Joh, Seung Kyu Park, Lori E Dodd, Jongseok Lee, Taeksun Song, Ying Cai, Lisa C Goldfeder, Laura E Via, Matthew W Carroll, Clifton E Barry 3rd, Sang-Nae Cho, Hongjo Choi, Myungsun Lee, Ray Y Chen, Youngran Kim, Soyoung Yoon, Joon Sung Joh, Seung Kyu Park, Lori E Dodd, Jongseok Lee, Taeksun Song, Ying Cai, Lisa C Goldfeder, Laura E Via, Matthew W Carroll, Clifton E Barry 3rd, Sang-Nae Cho

Abstract

Background: Tuberculosis remains an important health concern in many countries. The aim of this study was to identify predictors of unfavorable outcomes at the end of treatment (EOT) and at the end of study (EOS; 40 months after EOT) in South Korea.

Methods: New or previously treated tuberculosis patients were recruited into a prospective observational cohort study at two hospitals in South Korea. To identify predictors of unfavorable outcomes at EOT and EOS, logistic regression analysis was performed.

Results: The proportion of multidrug-resistant tuberculosis (MDR-TB) was 8.2% in new cases and 57.9% in previously treated cases. Of new cases, 68.6% were cured, as were 40.7% of previously treated cases. At EOT, diabetes, ≥3 previous TB episodes, ≥1 significant regimen change, and MDR-TB were significantly associated with treatment failure or death. At EOS, age ≥35, body-mass index (BMI) <18.5, diabetes, and MDR-TB were significantly associated with treatment failure, death, or relapse. Among cases that were cured at EOT, age ≥50 and a BMI <18.5 were associated with subsequent death or relapse during follow-up to EOS. Treatment interruption was associated with service sector employees or laborers, bilateral lesions on chest X-ray, and previous treatment failure or treatment interruption history.

Conclusions: Risk factors for poor treatment outcomes at EOT and EOS include both patient factors (diabetes status, age, BMI) and disease factors (history of multiple previous treatment episodes, MDR-TB). In this longitudinal, observational cohort study, diabetes mellitus and MDR-TB were risk factors for poor treatment outcomes and relapse. Measures to help ensure that the first tuberculosis treatment episode is also the last one may improve treatment outcomes.

Trial registration: ClinicalTrials.gov ID: NCT00341601.

References

    1. Snider DE, Roper WL. The New tuberculosis. N Engl J Med. 1992;14(10):703–705. doi: 10.1056/NEJM199203053261011.
    1. WHO. WHO/HTM/TB/2013.11. Geneva: World Health Organization; 2013. Global tuberculosis report 2013.
    1. World Health Organization. The global plan to stop TB 2011-2015: transforming the fight towards elimination of tuberculosis. Geneva: World Health Organization; 2010.
    1. Gandy M, Zumla A. The resurgence of disease: social and historical perspectives on the ‘new’tuberculosis. Soc Sci Med. 2002;14(3):385–396. doi: 10.1016/S0277-9536(01)00176-9.
    1. Lönnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med. 2009;14(12):2240–2246. doi: 10.1016/j.socscimed.2009.03.041.
    1. Shetty N, Shemko M, Vaz M, D’Souza G. An epidemiological evaluation of risk factors for tuberculosis in South India: a matched case control study. Int J Tuberc Lung Dis. 2006;14(1):80–86.
    1. Reed GW, Choi H, Lee SY, Lee M, Kim Y, Park H, Lee J, Zhan X, Kang H, Hwang S. Impact of Diabetes and Smoking on Mortality in Tuberculosis. PLoS One. 2013;14(2):e58044. doi: 10.1371/journal.pone.0058044.
    1. Kolappan C, Gopi PG. Tobacco smoking and pulmonary tuberculosis. Thorax. 2002;14(11):964–966. doi: 10.1136/thorax.57.11.964.
    1. Maciel EL, Brioschi AP, Peres RL, Guidoni LM, Ribeiro FK, Hadad DJ, Vinhas SA, Zandonade E, Palaci M, Dietze R, Johnson JL. Smoking and 2-month culture conversion during anti-tuberculosis treatment. Int J Tuberc Lung Dis. 2013;14(2):225–228. doi: 10.5588/ijtld.12.0426.
    1. Franke M, Appleton S, Bayona J, Arteaga F, Palacios E, Llaro K, Shin S, Becerra M, Murray M, Mitnick C. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis. 2008;14(12):1844–1851. doi: 10.1086/588292.
    1. Faustini A, Hall A, Perucci C. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax. 2006;14(2):158. doi: 10.1136/thx.2005.045963.
    1. Kim H-R, Hwang SS, Kim HJ, Lee SM, Yoo C-G, Kim YW, Han SK, Shim Y-S, Yim J-J. Impact of extensive drug resistance on treatment outcomes in Non—HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2007;14(10):1290–1295. doi: 10.1086/522537.
    1. Dalton T, Cegielski P, Akksilp S, Asencios L, Caoili JC, Cho SN, Erokhin VV, Ershova J, Gler MT, Kazennyy BY. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet. 2012;14(9851):1406–1417. doi: 10.1016/S0140-6736(12)60734-X.
    1. Kim DH, Kim HJ, Park S-K, Kong S-J, Kim YS, Kim T-H, Kim EK, Lee KM, Lee SS, Park JS Koh WJ, Lee CH, Kim JY, Shim TS. Treatment Outcomes and Long-term Survival in Patients with Extensively Drug-resistant Tuberculosis. Am J Respir Crit Care Med. 2008;14(10):1075–1082. doi: 10.1164/rccm.200801-132OC.
    1. Verver S, Warren RM, Beyers N, Richardson M, van der Spuy GD, Borgdorff MW, Enarson DA, Behr MA, van Helden PD. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med. 2005;14(12):1430–1435. doi: 10.1164/rccm.200409-1200OC.
    1. Millet JP, Shaw E, Orcau A, Casals M, Miro JM, Cayla JA. Barcelona Tuberculosis Recurrence Working G. Tuberculosis recurrence after completion treatment in a European city: reinfection or relapse? PLoS One. 2013;14(6):e64898. doi: 10.1371/journal.pone.0064898.
    1. World Health Organization. Treatment of tuberculosis guidelines 4th edition. Geneva: World Health Organization; 2010.
    1. KCDC. Guideline for tuberculosis control, 2010. Seoul: Korea Centers for Disease Control and Prevention (published in Korean); 2010.
    1. Kliiman K, Altraja A. Predictors and mortality associated with treatment default in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2010;14(4):454–463.
    1. Jeon C, Hwang S, Min J, Prevots D, Goldfeder L, Lee H, Eum S, Jeon D, Kang H, Kim J. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis. 2008;14(1):42–49. doi: 10.1086/524017.
    1. Shin S, Pasechnikov A, Gelmanova I, Peremitin G, Strelis A, Andreev Y, Golubchikova V, Tonkel T, Yanova G, Nikiforov M. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis. 2006;14(4):402–408.
    1. Kwon Y, Kim Y, Suh G, Chung M, Kim H, Kwon OJ, Choi Y, Kim K, Kim J, Shim YM, Koh WJ. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clinical Infectious Diseases. 2008;14(4):496–502. doi: 10.1086/590005.
    1. Shargie E, Lindtjorn B. Determinants of treatment adherence among smear-positive pulmonary tuberculosis patients in Southern Ethiopia. PLoS Med. 2007;14(2):e37. doi: 10.1371/journal.pmed.0040037.
    1. Hasker E, Khodjikhanov M, Usarova S, Asamidinov U, Yuldashova U, Werf M, Uzakova G, Veen J. Default from tuberculosis treatment in Tashkent, Uzbekistan; Who are these defaulters and why do they default? BMC Infect Dis. 2008;14(1):97. doi: 10.1186/1471-2334-8-97.
    1. Xu W, Lu W, Zhou Y, Zhu L, Shen H, Wang J. Adherence to anti-tuberculosis treatment among pulmonary tuberculosis patients: a qualitative and quantitative study. BMC Health Serv Res. 2009;14(1):169. doi: 10.1186/1472-6963-9-169.
    1. Volmink J, Garner P. Systematic review of randomised controlled trials of strategies to promote adherence to tuberculosis treatment. Br Med J. 1997;14(7120):1403–1406. doi: 10.1136/bmj.315.7120.1403.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren